Argus upgraded Cardinal Health to Buy from Hold.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Neurocrine price target raised to $154 from $150 at Canaccord
- Cardinal Health Board of Directors Approves Quarterly Dividend
- Precipio, Cardinal Health enter distribution agreement for HemeScreen portfolio
- Cardinal Health price target raised to $125 from $122 at UBS
- Cardinal Health price target raised to $109 from $96 at TD Cowen
Questions or Comments about the article? Write to editor@tipranks.com